Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (101-110 of 356) with videos related to

Pageof 36
Sort By:
American Journal of Respiratory and Critical Care Medicine|April 12, 2022
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary FibrosisGiacomo Sgalla, Tonia Magrì, Marialessia Lerede, et al.
American Journal of Respiratory and Critical Care Medicine|June 28, 2019
Statin Therapy and Lung DisordersPier-Valerio Mari, Francesco Lombardi, Maria Chiara Flore, et al.
Lung India : Official Organ of Indian Chest Society|January 28, 2015
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosisZarir F Udwadia, Jai B Mullerpattan, Canchi Balakrishnan, et al.
Respiration; International Review of Thoracic Diseases|September 24, 2023
The Impact of Telemedicine during Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic and Future Perspectives: A Systematic ReviewGiorgio Monteleone, Giovanni Terzulli, Francesca Cefaloni, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2011
A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis?Giovanni Ferrara, Shreemanta K Parida, Alimuddin Zumla, et al.
European Journal of Internal Medicine|June 26, 2012
The role of biomarkers in low respiratory tract infectionsFrancesco Blasi, Marialuisa Bocchino, Fabiano Di Marco, et al.
The European Respiratory Journal|August 2, 2014
A global registry for idiopathic pulmonary fibrosis: the time is nowChristopher J Ryerson, Tamera J Corte, Harold R Collard, et al.
American Journal of Respiratory and Critical Care Medicine|October 16, 2015
Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?Luca Richeldi, Florence Le Maulf, Rozsa Schlenker-Herceg, et al.
Recenti Progressi in Medicina|May 17, 2006
[New tools for a better diagnosis of latent tuberculosis infection]Giovanni Ferrara, Monica Losi, Pietro Roversi, et al.
BMC Pulmonary Medicine|October 7, 2025
Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort studyFrancesca Lalla, Angelo Latella, Francesco Varone, et al.
Pageof 36

Showing results (101-110 of 356) with videos related to

Sort By:
Pageof 36
American Journal of Respiratory and Critical Care Medicine|April 12, 2022
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary FibrosisGiacomo Sgalla, Tonia Magrì, Marialessia Lerede, et al.
American Journal of Respiratory and Critical Care Medicine|June 28, 2019
Statin Therapy and Lung DisordersPier-Valerio Mari, Francesco Lombardi, Maria Chiara Flore, et al.
Lung India : Official Organ of Indian Chest Society|January 28, 2015
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosisZarir F Udwadia, Jai B Mullerpattan, Canchi Balakrishnan, et al.
Respiration; International Review of Thoracic Diseases|September 24, 2023
The Impact of Telemedicine during Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic and Future Perspectives: A Systematic ReviewGiorgio Monteleone, Giovanni Terzulli, Francesca Cefaloni, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2011
A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis?Giovanni Ferrara, Shreemanta K Parida, Alimuddin Zumla, et al.
European Journal of Internal Medicine|June 26, 2012
The role of biomarkers in low respiratory tract infectionsFrancesco Blasi, Marialuisa Bocchino, Fabiano Di Marco, et al.
The European Respiratory Journal|August 2, 2014
A global registry for idiopathic pulmonary fibrosis: the time is nowChristopher J Ryerson, Tamera J Corte, Harold R Collard, et al.
American Journal of Respiratory and Critical Care Medicine|October 16, 2015
Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?Luca Richeldi, Florence Le Maulf, Rozsa Schlenker-Herceg, et al.
Recenti Progressi in Medicina|May 17, 2006
[New tools for a better diagnosis of latent tuberculosis infection]Giovanni Ferrara, Monica Losi, Pietro Roversi, et al.
BMC Pulmonary Medicine|October 7, 2025
Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort studyFrancesca Lalla, Angelo Latella, Francesco Varone, et al.
Pageof 36